MoonLake Immunotherapeutics (MLTX) Change in Acquisitions & Divestments (2022 - 2026)

MoonLake Immunotherapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $59.2 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 59.15% year-over-year to $59.2 million in Q1 2026; TTM through Mar 2026 was $382.7 million, a 65.75% increase from a year earlier, with the FY2025 full-year figure at $468.4 million, up 222.58% from the prior year.
• Change in Acquisitions & Divestments grew to $59.2 million in Q1 2026 per MLTX's latest filing, from $29.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $205.9 million in Q2 2025 and bottomed at -$1.3 million in Q2 2024.
• The 5-year median for Change in Acquisitions & Divestments is $44.2 million (2024), against an average of $59.5 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 110.26% in 2024 and jumped 15927.29% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $9.9 million in 2022, then surged by 1083.17% to $117.2 million in 2023, then sank by 100.18% to -$211000.0 in 2024, then surged by 13965.4% to $29.3 million in 2025, then surged by 102.24% to $59.2 million in 2026.
• Per Business Quant, the three latest MLTX Change in Acquisitions & Divestments figures stand at $59.2 million (Q1 2026), $29.3 million (Q4 2025), and $88.4 million (Q3 2025).